Expert Ratings For Bio-Rad Laboratories
Portfolio Pulse from Benzinga Insights
Bio-Rad Laboratories (NYSE:BIO) has been evaluated by 5 analysts over the past three months, with ratings ranging from bullish to indifferent. The average 12-month price target has increased by 4.17% to $378.4. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite these positive analyst actions, Bio-Rad faces financial challenges, including a revenue decline of -6.26%, a net margin of -339.16%, and an ROE of -27.36%.
October 01, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Rad Laboratories has received mixed analyst ratings, with a recent increase in the average price target to $378.4. Despite positive analyst sentiment, the company faces significant financial challenges, including a revenue decline and negative profitability metrics.
The mixed analyst ratings and increased price target suggest some positive sentiment, but the company's financial challenges, such as declining revenue and negative margins, offset this. The short-term impact on the stock price is likely neutral as the market weighs these factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100